China, Sept. 8 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Randomized, Double-Blind, Controlled Clinical Trial of Vebreltinib in Patients with IDH-Mutant Residual or Recurrent Low-Grade Glioma'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600131917
Registration Time: 2026/09/07
Type: Interventional study
Primary Sponsor: Beijing Tiantan Hospital, Capital Medical University
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=341125
Published by HT Digital Content Services with permission from Health Daily Digest....